Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Completed

Conditions: Chromaffin-tissue Derived Tumors

Treatments: Other: Scintigraphy in 123I-IBZM

Study type: Interventional

Funder types: Other

Identifiers

NCT00875407

2008/09

2008-A007932-52

Details and patient eligibility

About

Context. Nuclear imaging plays a central role in management of chromaffin-tissue derived tumors because tumor cells exhibit peptide receptors and proteins involved in metabolism that can be targeted with specific radiopharmaceutics. Recently, over expression dopamine-receptor D2 isoforms has been found in endocrine tumors.

Objective. The aim of the present study is to evaluate the feasibility of 123I-IBZM (a D2 agonist radiolabelled with 123I) in patients with PHEO and/or PGL. Diagnostic accuracy will be also compared to traditional SPECT imaging procedures.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age + 18 years. The women in ages to procreate have to have an effective contraception or a negative pregnancy test (in the absence of effective contraception) Having a radiological and functional imaging (balance sheet(assessment) pré--IBZM) considered adapted and complete for the pathology.
• Having a phéochromocytome or a paragangliome proving a surgical operation in view of the data of the balance sheet(assessment) pré--IBZM.
• With or without allergy in the iodine.

Exclusion criteria

• NEM2A or 2B.
• Malignant Forms which do not recover from an even partial, surgical gesture(movement).
• Pregnant Women or in the course of feeding.
• Women in age to procreate without effective contraception, with positive pregnancy test.
• Renal insufficiency

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)